Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | ASO tominersen for Huntington’s disease in Phase III trials

Edward Wild, MA, MB BChir, FRCP, PhD, UCL Queen Square Institute of Neurology, London, UK, discusses the root cause of Huntington’s disease via the protein huntingtin and how antisense oligonucleotides (ASOs) can target it. Tominersen, previously called RG6042, shows potential and is currently in Phase III efficacy clinical trials (NCT03761849). This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).